Ownership and insider activity for Compugen Ltd. (CGEN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe.
Price
| Price | $2.41 |
| Market Cap | $228M |
| Exchange | NASDAQ |
| Country | IL |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-29 | Levine Zurit | A-Award | 18,000 | |
| 2026-07-29 | Levine Zurit | A-Award | 24,000 | $54K |
| 2026-07-29 | Silberman David | A-Award | 19,500 | |
| 2026-07-29 | Silberman David | A-Award | 26,000 | $59K |
| 2026-07-29 | Ophir Eran | A-Award | 200,000 | $452K |
| 2026-07-29 | Cohen-Dayag Anat | A-Award | 100,000 | $226K |
| 2026-07-29 | Perry Eran | A-Award | 7,500 | |
| 2026-07-29 | Perry Eran | A-Award | 10,000 | $23K |
| 2026-07-29 | Ferre Pierre | A-Award | 70,000 | $280K |
| 2026-07-29 | Kredo Russo Sharon | A-Award | 18,000 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $61.5M | $30.4M | $45.7M | $9.8M | $7.1M | $7.8M | $11.1M | $13.9M | $18.2M | $90.6M |
| Short-term Investments | 0 | 0 | 0 | $34.0M | $116.6M | $109.2M | $72.3M | $36.8M | $85.0M | $55.0M |
| Receivables | $82000 | $51000 | $167000 | $341000 | $2.0M | $188000 | $317000 | $61.3M | $269000 | $294000 |
| Inventory | -$2.1M | -$1.7M | -$1.3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $62.7M | $31.2M | $46.6M | $45.0M | $129.1M | $123.2M | $86.1M | $114.6M | $106.0M | $148.0M |
| Property, Plant & Equipment | $6.0M | $4.6M | $3.4M | $5.6M | $4.5M | $3.9M | $3.4M | $2.5M | $3.7M | $3.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $71.1M | $38.7M | $53.2M | $53.8M | $138.3M | $132.2M | $94.2M | $121.3M | $115.0M | $156.9M |
| Accounts Payable | $1.3M | $3.4M | $2.9M | $1.1M | $1.4M | $4.6M | $1.8M | $3.5M | $1.8M | $2.4M |
| Short-term Debt | 0 | 0 | 0 | $600000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $4.7M | $6.2M | $10.0M | $6.8M | $10.5M | $17.1M | $11.9M | $26.3M | $20.2M | $22.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $7.6M | $9.4M | $15.9M | $15.4M | $18.5M | $25.5M | $16.5M | $55.8M | $60.1M | $54.1M |
| Retained Earnings | -$271.0M | -$308.2M | -$330.8M | -$358.2M | -$387.9M | -$422.1M | -$455.8M | -$474.5M | -$488.8M | -$453.4M |
| Total Equity | $63.5M | $29.3M | $37.2M | $38.3M | $119.8M | $106.7M | $77.7M | $65.6M | $54.9M | $102.7M |
| Total Debt | 0 | 0 | 0 | $3.6M | $3.2M | $2.8M | $1.9M | $1.4M | $2.9M | $3.0M |
| Net Debt | -$61.5M | -$30.4M | -$45.7M | -$40.3M | -$120.6M | -$114.3M | -$81.4M | -$49.3M | -$100.3M | -$142.7M |
| Working Capital | $57.9M | $25.0M | $36.6M | $38.2M | $118.6M | $106.1M | $74.2M | $88.3M | $85.8M | $125.5M |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 5.72 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -0.38 |
Profitability
| Return on Equity | 42.57% |
| Return on Invested Capital | 26.00% |
| Return on Assets | 25.43% |
| Gross Margin | 86.89% |
| Operating Margin | 40.94% |
| Net Margin | 47.55% |
Related companies: CRBP · CRDF · CYBN · IPHA · MIST · MOLN · NVCT
Explore sector: Healthcare · Biotechnology
More sections of CGEN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks